Phase 4 N=20 Treatment of Nicotine Dependence and Acute Depression
Major Depressive Disorder · Nicotine Dependence
Primary: Hamilton Depression Scale Score — -.5322 percentage of change in depression — p=<.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=24 Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
Coronary Artery Disease
Primary: Change From Baseline in ADP-mediated Platelet Aggregation, APP, SFFLRN, AYPGKF. — 84; 38; 94; 53 % inhibitn of platelet aggregation — p=0.001
Phase 4 N=85 Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics
Insulin Secretion · Insulin Resistance
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -1.08 percentage
Phase 4 N=78 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)
Adult Growth Hormone Deficiency
Primary: Percentage of Subjects Developing Binding Antibodies (BAbs) to Saizen® — 0 percentage of subjects
Phase 4 N=15 Preventing Depression in People Receiving Mechanical Ventilation in an Intensive Care Unit
Depression
Primary: Recruitment Feasibility, Defined as the Number of Participants Recruited and Administered a Medication Dose Within 48 Hours of Mechanical Ventilation — 7; 8 participants
Phase 4 N=18 PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Plaque Psoriasis
Primary: Cmax of Calcitriol Plasma Level — 120.7 pg/mL
Phase 4 N=64 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism
Polycystic Ovary Syndrome
Primary: Biochemical Assessment of Hyperandrogenism — 0.7; 0.7 Index — p=<.0001
Phase 4 N=88 Study of the Durability of Glycemic Control With Nateglinide
Type 2 Diabetes Mellitus
Primary: The Durability of Nateglinide in Comparison With Those of Glimepiride Based on the Withdrawal Rate — 10; 7 Participants
Phase 4 N=19 Plaque Psoriasis Study in Pediatric Subjects
Plaque Psoriasis
Primary: Success of Investigator's Global Assessment (IGA) — 3; 7 Participants
Phase 4 N=915 Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Rheumatoid Arthritis
Primary: Percentage of Subjects Who Met the American College of Rheumatology 20 % (ACR20) Criteria at Week 12 — 69.2; 71.4 Percentage of subjects — p==0.467
Phase 4 N=11 An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder
Bipolar Disorder
Primary: Number of Participants With Serious Adverse Events (SAEs) — 0 Participants
Phase 4 N=61 Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris
Acne Vulgaris
Primary: Adherence to Treatment — 64; 38; 28; 52 Percent of prescribed doses
Phase 4 N=82 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.
Acellular Pertussis · Tetanus · Diphtheria
Primary: Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations Above the Cut-offs — 61; 5; 17; 0 Subjects
Phase 4 N=8 Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5
End-Stage Renal Disease · Stage 5 Chronic Kidney Disease
Primary: Cmax of Telavancin — 33.1; 38.1 mcg/mL
Phase 4 N=38 Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?
Larynx Disease · Gastroesophageal Reflux
Primary: Number of Patients With Dilation of Intracellular Spaces 3 Months After Therapy — 0 participants